Satraplatin

Research use only, not for human use.

Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis.

Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis; shows similar cytotoxicity and pattern of cytotoxicity to cisplatin against human ovarian carcinoma cell lines (IC50=1.7 uM); shows antitumor selectivity far superior to cisplatin, carboplatin, or tetraplatin in vivo; orally active. Chemotherapeutic Agents, Phase 2 Clinical

BMS-182751;BMY-45594;JM-216

Cell Cycle/DNA Damage

DNA Alkylator

DNA Alkylator

Cancer

Chemotherapeutic

129580-63-8

500.28

C10H22Cl2N2O4Pt+2

>98% (HPLC)

DMSO: ≥ 33 mg/mL

CC(O[Pt]([NH2]C1CCCCC1)(Cl)(Cl)([NH3])OC(C)=O)=O

Platinum, bis(acetato-κO)amminedichloro(cyclohexanamine)-, (OC-6-43)- (9CI)

(-20℃)

With Ice Pack

≥ 2 years